Specific Behaviors

Smoking (SRNT materials recommended by Geof Williams)

Other Tobacco articles (suggested by Geof Williams)

Measurement aspects:

Hall SM, Delucchi KL, Velicier WF, Kahler CW, Ranger-Moore J, Hedeker D, Tsoh JY, Niaura R. Statistical analysis of randomized trials in tobacco treatment; longitudinal designs with dichotomous outcome.  Nicotine and Tobacco Research. 2001;3:193-202.

Hatsukami DK.  Introduction: Tobacco treatment outcome methodology papers - a series. Nicotine and Tobacco Research. 2001;3:191.

SRNT Subcommittee on Biochemical Verification.  Biochemical verification of
tobacco use and cessation. Nicotine & Tobacco Research. 2002;4:149-159.

Hughes, J. R., Keely, J. P., Niaura, R. A., Ossip-Klein, D. J., Richmond, R. L., Swan, G. E. (2003). Measures of abstinence in Clinical Trials: Issues and Recommendations. Nicotine and Tobacco Research, 5, 13-25.

Pierce JP, Gilpin EA. A minimum 6-month prolonged abstinence should be required for evaluating smoking cessation trials.  Nicotine & Tobacco Research. 2003;5:151-153.

Mermelstein, R., Colby, S.M., Patten, C., Prokhorov, A., Brown, R., Myers, M., Adelman, W., Hudmon, K., Mcdonald, P. (2002) Methodological issues in measuring treatment outcome in adolescent smoking cessation studies.  Nicotine & Tobacco Research, 4(4), 395-403.

Williams GC, McGregor H, Borrelli B, Jordan PJ, and Stretcher V. “Measuring Tobacco Dependence Treatment Outcomes: A Perspective from the Behavioral Change Consortium. Annals of Behavioral Medicine. Forthcoming 2004.

Genetic aspects:

Ring  HZ and Kroetz  DL. Candidate Genes Approach for Pharmacogenetic Studies. Pharmacogenomics 3 (1): 1-10, 2002.

Walton R, Johnstone E, Munafo M, Neville M, and Griffiths S. Genetic Clues to the Molecular Basis of Tobacco Addition and Progress Towards Personalized Therapy. Trends in Molecular Medicine 7 (2): 70-76, 2001.